Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Phillips Wealth Planners LLC

Phillips Wealth Planners LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,682 shares of the biopharmaceutical company’s stock after acquiring an additional 193 shares during the quarter. Phillips Wealth Planners LLC’s holdings in Gilead Sciences were worth $406,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Farther Finance Advisors LLC boosted its stake in shares of Gilead Sciences by 3.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 17,775 shares of the biopharmaceutical company’s stock worth $1,490,000 after purchasing an additional 547 shares during the last quarter. Lowe Brockenbrough & Co. Inc. boosted its position in Gilead Sciences by 12.4% during the third quarter. Lowe Brockenbrough & Co. Inc. now owns 7,768 shares of the biopharmaceutical company’s stock worth $651,000 after acquiring an additional 858 shares during the last quarter. Roanoke Asset Management Corp NY boosted its holdings in shares of Gilead Sciences by 1.4% during the third quarter. Roanoke Asset Management Corp NY now owns 34,561 shares of the biopharmaceutical company’s stock worth $2,898,000 after purchasing an additional 462 shares during the last quarter. Affinity Investment Advisors LLC increased its stake in Gilead Sciences by 2.0% in the third quarter. Affinity Investment Advisors LLC now owns 19,974 shares of the biopharmaceutical company’s stock valued at $1,675,000 after purchasing an additional 385 shares during the last quarter. Finally, Human Investing LLC lifted its position in Gilead Sciences by 6.0% during the third quarter. Human Investing LLC now owns 3,463 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 195 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Truist Financial raised their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 price objective on shares of Gilead Sciences in a research report on Tuesday. Ten analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $86.85.

Gilead Sciences Stock Up 0.8 %

Gilead Sciences stock opened at $89.51 on Friday. The firm has a market capitalization of $111.44 billion, a P/E ratio of 109.16, a P/E/G ratio of 3.07 and a beta of 0.18. The company has a 50-day simple moving average of $83.79 and a 200-day simple moving average of $74.12. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $89.74. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The company had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. As a group, equities analysts expect that Gilead Sciences, Inc. will post 3.76 earnings per share for the current year.

Insider Activity

In other news, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,847 shares of company stock worth $3,033,340. 0.16% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.